Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.45 |
| ▸ | CDK1 | P06493 | 4/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27437305 | 0.90 | CLK1 (0.39) | CDK2CDK1CCNB1CCNE1SMN1; SMN2 | |
| SCHEMBL18257684 | 0.80 | CLK1 (0.46) | CDK2CDK1CCNB1CCNE1ADORA2A | |
| SCHEMBL24328067 | 0.78 | CDK1 (0.41) | CDK2CDK1CCNB1CCNE1SMN1; SMN2 | |
| SCHEMBL19757296 | 0.78 | CLK1 (0.45) | CDK2CDK1CCNB1CCNE1SMN1; SMN2 | |
| SCHEMBL18471001 | 0.76 | CLK1 (0.40) | SMN1; SMN2DYRK1API4KAPI4K2BPI4K2A | |
| SCHEMBL26828308 | 0.71 | CLK1 (0.44) | DYRK1ACLK1CDK5CDK5R1 | |
| SCHEMBL24328076 | 0.71 | SMN1; SMN2 (0.44) | CDK2CDK1CCNB1CCNE1SMN1; SMN2 | |
| SCHEMBL7091031 | 0.70 | SMN1; SMN2 (0.46) | CDK2CDK1CCNB1CCNE1SMN1; SMN2 | |
| SCHEMBL7035601 | 0.70 | SMN1; SMN2 (0.46) | CDK2CDK1CCNB1CCNE1SMN1; SMN2 | |
| SCHEMBL24328077 | 0.70 | CDK1 (0.42) | CDK2CDK1CCNB1CCNE1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218365-A1 | FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE | THE PROGERIA RESEARCH FOUNDATION, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4306538-A2 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | Sarepta Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3297649-B1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SAREPTA THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230310625-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-10-05 | — | — | US | disclosed |
| US-20230310625-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-10-05 | — | — | US | disclosed |
| US-11672871-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2023070086-A1 | MORPHOLINO OLIGOMERS FOR TREATMENT OF PERIPHERAL MYELIN PROTEIN 22 RELATED DISEASES | SAREPTA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-3389719-B1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SAREPTA THERAPEUTICS INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210290772-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | SAREPTA THERAPEUTICS, INC. | 2021-09-23 | — | — | US | disclosed |
| WO-2021150867-A1 | DESIGNING ANTISENSE OLIGONUCLEOTIDE DELIVERY PEPTIDES BY INTERPRETABLE MACHINE LEARNING | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| US-20200316210-A1 | Cell-Penetrating Peptides For Antisense Delivery | SAREPTA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200237922-A1 | BICYCLIC PEPTIDE OLIGONUCLEOTIDE CONJUGATES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-07-30 | — | — | US | disclosed |
| WO-2019178479-A1 | CHIMERIC PEPTIDES FOR ANTISENSE DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190030176-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SAREPTA THERAPEUTICS, INC. | 2019-01-31 | — | — | US | disclosed |
| US-20180214567-A1 | Peptide Oligonucleotide Conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| WO-2017106304-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SAREPTA THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200237922-A1 | BICYCLIC PEPTIDE OLIGONUCLEOTIDE CONJUGATES | MUSK, MTPN, TNNC1 | CDK2 3617/4885CDK1 2676/4885CCNB1 2022/4885 |
| US-20200316210-A1 | Cell-Penetrating Peptides For Antisense Delivery | MYOF, TNNC1, MTPN | CDK2 4859/4885CDK1 4637/4885CCNB1 3621/4885 |
| US-20180214567-A1 | Peptide Oligonucleotide Conjugates | MYOF, MUSK, MTPN | CDK2 4610/4885CDK1 3950/4885CCNB1 3383/4885 |
| US-20230310625-A1 | Peptide Oligonucleotide Conjugates | MYOF, MUSK, MTPN | CDK2 4610/4885CDK1 3950/4885CCNB1 3383/4885 |
| US-11672871-B2 | Peptide oligonucleotide conjugates | MYOF, MUSK, MTPN | CDK2 4610/4885CDK1 3950/4885CCNB1 3383/4885 |
| US-20190030176-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SMN1; SMN2, MUSK, MYOF | CDK2 4746/4885CDK1 4004/4885CCNB1 3431/4885 |
| US-20210290772-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | MTPN, MYOF, IAPP | CDK2 4623/4885CDK1 4577/4885CCNB1 3598/4885 |
| US-20240218365-A1 | FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE | POLB, GBA1, POLN | CDK2 3982/4885CDK1 3810/4885CCNB1 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.